ARCT (Arcturus Therapeutics Holdings) Quality Rank


ARCT Arcturus Therapeutics Holdings Inc ARCT
56 GF Score
Price $7.27
GF Value $4.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Arcturus Therapeutics Holdings Quality Rank Related Terms

ARCT
56GF Score
Arcturus Therapeutics Holdings Inc ARCT
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $7.27 is trading 76% above its estimated GF Value™ of $4.13. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Quality Rank:
  • GF Value™: $4.13 vs. price of $7.27 (76% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score

Get the complete analysis for ARCT

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.27
Price
$4.13
GF Value